JP2022554230A5 - - Google Patents

Info

Publication number
JP2022554230A5
JP2022554230A5 JP2022524568A JP2022524568A JP2022554230A5 JP 2022554230 A5 JP2022554230 A5 JP 2022554230A5 JP 2022524568 A JP2022524568 A JP 2022524568A JP 2022524568 A JP2022524568 A JP 2022524568A JP 2022554230 A5 JP2022554230 A5 JP 2022554230A5
Authority
JP
Japan
Prior art keywords
methylumbelliferone
derivatives
salts
use according
allyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022524568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554230A (ja
JP7883950B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/079979 external-priority patent/WO2021078991A1/en
Publication of JP2022554230A publication Critical patent/JP2022554230A/ja
Publication of JP2022554230A5 publication Critical patent/JP2022554230A5/ja
Application granted granted Critical
Publication of JP7883950B2 publication Critical patent/JP7883950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022524568A 2019-10-25 2020-10-25 神経系の状態の処置 Active JP7883950B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926001P 2019-10-25 2019-10-25
US62/926,001 2019-10-25
PCT/EP2020/079979 WO2021078991A1 (en) 2019-10-25 2020-10-25 Treatment of conditions of the nervous system

Publications (3)

Publication Number Publication Date
JP2022554230A JP2022554230A (ja) 2022-12-28
JP2022554230A5 true JP2022554230A5 (cg-RX-API-DMAC7.html) 2023-11-06
JP7883950B2 JP7883950B2 (ja) 2026-07-02

Family

ID=73455660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524568A Active JP7883950B2 (ja) 2019-10-25 2020-10-25 神経系の状態の処置

Country Status (5)

Country Link
US (1) US20220380331A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048257A1 (cg-RX-API-DMAC7.html)
JP (1) JP7883950B2 (cg-RX-API-DMAC7.html)
CN (1) CN115023222A (cg-RX-API-DMAC7.html)
WO (1) WO2021078991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4440571A1 (en) * 2021-11-30 2024-10-09 Evexys Biotech OY Prevention and treatment of depressive disorders and conditions promoted by protease containing plasma extracellular vesicles (pcpev)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810016D0 (en) * 1998-05-08 1998-07-08 Smithkline Beecham Plc Compounds
BRPI0609265A2 (pt) * 2005-03-29 2010-03-09 Newron Pharm Spa derivados de aminoalquil-e amidoalquil-benzopiran substituìdos
CN103446154A (zh) * 2012-05-29 2013-12-18 中国医学科学院药物研究所 香豆素衍生物在防治脑部重大疾病中的应用
US10285976B2 (en) * 2013-08-12 2019-05-14 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone treatment for immune modulation
US10370400B2 (en) * 2017-01-13 2019-08-06 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone derivatives for treatment for immune modulation
US11278518B2 (en) * 2017-01-13 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatment using 4-methylumbelliferone and derivatives thereof

Similar Documents

Publication Publication Date Title
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
KR101605151B1 (ko) 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
AU2008322595B2 (en) Method of treating arthritis
JP2009521494A5 (cg-RX-API-DMAC7.html)
JP2010500376A5 (cg-RX-API-DMAC7.html)
JP2018515495A5 (cg-RX-API-DMAC7.html)
US10493097B2 (en) Silicate containing compositions and methods of treatment
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2002111355A (ru) Производные 5бета-сапогенина и псевдосапогенина и их применение при лечении деменции
JP7471685B2 (ja) 新規な化合物およびそれを含むがんの予防または治療用薬学組成物
BRPI0823522A2 (pt) Uso de um composto derivado de ceramida
JP2019505529A5 (cg-RX-API-DMAC7.html)
JP2012510985A5 (cg-RX-API-DMAC7.html)
JP2015522592A5 (cg-RX-API-DMAC7.html)
CN105209037A (zh) 用于治疗癌症、神经障碍和纤维化病症的脂类呋喃、吡咯和噻吩化合物
WO2016203468A1 (en) Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
JP5017268B2 (ja) 覚醒を改善する方法
CN114344313A (zh) 用于预防或治疗神经系统退行性疾病的白桦脂酸衍生物
EP3288932A1 (en) Novel epha4 inhibitors targeting its ligand binding domain
RU2732417C1 (ru) Производные фенотиазина и способы их применения
WO2019028270A1 (en) MATERIALS AND METHODS FOR DELETING AND / OR TREATING BONE-RELATED DISEASES AND SYMPTOMS
RU2006104241A (ru) Пароксетин холат или соли производных холевой кислоты и композиция содержащая пароксетин и холевую кислоту или производные холевой кислоты
EP4048663A1 (en) Quinolone carboxylic derivatives
CN1879619A (zh) 癌症治疗
RU2470939C2 (ru) Полипептидное соединение